Gremubamab

Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections[1][2].

Product Specifications

CAS Number

[1800381-36-5]

Product Name Alternative

MEDI3902

UNSPSC

12352203

Target

Bacterial

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/gremubamab.html

Purity

95.0

Solubility

10 mM in DMSO

Smiles

[Gremubamab]

Molecular Weight

(200.46 kDa)

References & Citations

[1]Chastre J, et al. Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial. Crit Care. 2022 Nov 15;26 (1) :355. |[2]Le HN, et al. Treatment Efficacy of MEDI3902 in Pseudomonas aeruginosa Bloodstream Infection and Acute Pneumonia Rabbit Models. Antimicrob Agents Chemother. 2019 Jul 25;63 (8) :e00710-19.